Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Patheon to Manufacture FDA-Approved Nasal Spray | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Patheon to Manufacture FDA-Approved Nasal Spray

Evoke Pharma initiates commercial manufacturing of Gimoti with the CDMO.

By: Contract Pharma

Contract Pharma Staff

Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, has initiated the commercial manufacturing of Gimoti (metoclopramide) nasal spray with its manufacturing partner, Patheon, a division of Thermo Fisher Scientific. Gimoti was approved by the U.S. FDA on June 19, 2020 for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The company plans to launch sales of Gimoti in the fourth quarter 2020 with its partner Eversana.
 
“We have continued to accelerate the necessary pre-commercialization activities for Gimoti alongside our commercial and manufacturing partners,” said David Gonyer, president and chief executive officer, Evoke Pharma. “Together with Patheon, we have initiated manufacturing process for the first commercial batch of Gimoti. We expect these activities to be completed over the next several weeks and ahead of our planned launch in the fourth quarter of 2020.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters